Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development

Mar 21 2023

Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome

Mar 16 2023


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
ACW $0.07 $0.16 $0.04

$0.15

AFP AFT PHARMACEUTICALS LIMITED $3.20 $3.77 $2.90

$3.16

ANP ANTISENSE THERAPEUTICS LIMITED $0.09 $0.15 $0.07

$0.26

ARX AROA BIOSURGERY LIMITED $1.04 $1.25 $0.63

$1.51

AVH AVITA MEDICAL INC $3.92 $4.41 $0.00

$5.217

CSL CSL LIMITED $288.94 $xx.xx $xx.xx xx.x xx.xx
GSS GENETIC SIGNATURES LIMITED $0.78 $xx.xx $xx.xx xx.x xx.xx
IMM IMMUTEP LIMITED $0.26 $xx.xx $xx.xx xx.x xx.xx
IMU IMMUTEP LIMITED $0.13 $xx.xx $xx.xx xx.x xx.xx
MAP MICROBA LIFE SCIENCES LIMITED $0.34 $xx.xx $xx.xx xx.x xx.xx
MDC MEDLAB CLINICAL LIMITED $6.60 $xx.xx $xx.xx xx.x xx.xx
MSB MESOBLAST LIMITED $0.94 $xx.xx $xx.xx xx.x xx.xx
MVP MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED $1.16 $xx.xx $xx.xx xx.x xx.xx
MYX MAYNE PHARMA GROUP LIMITED $3.50 $xx.xx $xx.xx xx.x xx.xx
NEU MAYNE PHARMA GROUP LIMITED $13.15 $xx.xx $xx.xx xx.x xx.xx
OCC MAYNE PHARMA GROUP LIMITED $0.37 $xx.xx $xx.xx xx.x xx.xx
PAR PARADIGM BIOPHARMACEUTICALS LIMITED $1.36 $xx.xx $xx.xx xx.x xx.xx
PBP PROBIOTEC LIMITED $2.40 $xx.xx $xx.xx xx.x xx.xx
PNV POLYNOVO LIMITED $1.81 $xx.xx $xx.xx xx.x xx.xx
PXS POLYNOVO LIMITED $0.05 $xx.xx $xx.xx xx.x xx.xx
SPL STARPHARMA HOLDINGS LIMITED $0.48 $xx.xx $xx.xx xx.x xx.xx
TLX TELIX PHARMACEUTICALS LIMITED $7.03 $xx.xx $xx.xx xx.x xx.xx
TRP TISSUE REPAIR LIMITED $0.20 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Dr Boreham’s Crucible: Actinogen Medical

Nov 30 2022

Actinogen Medical is a biotech with a potentially “gazillion” dollar opportunity in its Alzheimer’s drug


Dr Boreham’s Crucible: Qbiotics Group

Nov 09 2022

Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers


Dr Boreham’s Crucible: Pharmaxis

Oct 05 2022

Pharmaxis might be two clinical studies away from rehabilitation, reports Tim Boreham


Brokers Review Prospects For CSL

Sep 30 2022

Brokers remain generally upbeat on CSL and focus upon the earnings contribution from the Vifor Pharma acquisition 


Dr Boreham’s Crucible: Inoviq Ltd

Sep 19 2022

Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd


CSL: Offering Buying Opportunity

Sep 13 2022

Michael Gable of Fairmont Equities notes price action suggests CSL is a buying opportunity, and more so on a breakout


Dr Boreham’s Crucible: Vaxxas Pty Ltd

Sep 07 2022

Vaxxas is still unlisted, but worth highlighting as yet another Australian success story looks to be unfolding, reports Tim Boreham


Dr Boreham’s Crucible: Telix Pharmaceuticals

Aug 22 2022

Telix Pharmaceuticals’ prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions


Dr Boreham’s Crucible: Orthocell

Jul 26 2022

Micro-cap biotech Orthocell is aiming to emulate the successful growth story of Polynovo, nowadays capitalised at $1.1bn


CSL: Buy Trigger Ahead

Apr 26 2022

Michael Gable of Fairmont Equities notes that after two years in the lockdown doldrums, CSL is getting ready to break out